PART B: VALORISATION PLAN
SECTION I: ESTIMATION OF COSTS
|1||Taking into account the rest of the cost evaluation please provide an overall estimation of the total costs for full deployment/production of the R & D result.|
|In this section we expect an analysis of funding needed or expected for valorization of the R&D result. An estimation is expected (range of costs not obviously exact amounts)|
|… in terms of IPR protection|
|A software can’t be protected by a patent.
Within European Union member states, indeed, a computer-implemented inventions which only solve a business problem using a computer, rather than a technical problem, are considered unpatentable as lacking an inventive step.
Software is protected as works of literature under the Berne Convention. This allows the creator to prevent another entity from copying the program and there is generally no need to register code in order for it to be copyrighted.
So, in this case the protection does not provide significant costs.
|…in terms of product development|
In terms of product development, CRO needs a software developer (35.000 €).
Moreover CRO has to consider the certification costs, that are not quantifiable at the moment.
|…in terms of mass production|
There are not specific mass production costs
|… in terms of marketing|
miCRO will be promoted via web, so the marketing costs will be very low.
|2||Based on the above assessment as well as the marketing information please provide the correct estimation of the price for R&D product in correlation with costs|
|Year 1||Year 2||Year 3||Year 4||Year 5|
|Other running costs||3.500||6.000||10.000||15.000||20.000|
|TOTAL EXPECTED COSTS||48.500||51.000||65.000||95.000||100.000|
|Price per Unit||1.000||1.000||1.000||1.000||1.000|
|Type of Unit|
|Number of Units||35||60||100||150||200|
|TOTAL Expected Revenues||35.000||60.000||100.000||150.000||200.000|
|CASH FLOW REQUIRED (REVENUES-COSTS)||(13.500)||9.000||35.000||55.000||100.000|
|TOTAL CAPITAL required for five years||13.500|
SECTION 2: QUALITATIVE FACTORS
|4||Dimension of identified target groups|
|An estimation of the proportion of the target market (described in Section 3) which we expect to take|
In Italy: there are 33 excellence hospitals for chemotherapy and other medical therapies, but there are more than 150 hospitals with an oncology unit
So we can estimate a market of about 200 users in Italy
From this starting point, we can estimate more than 150.000 units all around the world.
A cautious target market can be 1.500 unit (that is 1% of 150.000)
|6||Evaluation of financial Risks for R&D result|
The project has no particular financial risks, because it doesn’t need any investment in fixed assets.
SECTION 3: IDENTIFICATION OF FINANCING SOURCES
After evaluating all the above mentioned criteria, please tick the best financing source for the achievement of R&D result (i.e. own capitals, banking credits, venture capital, business angels, etc)
|1. European Funding
Define relevance of the product with the following potential funding sources and comment
|Note: INTERVALUE partners are expected to pre-define a list of existing European funding sources for product development available for the country and advisors will check whether the proposed product is relevant for that funding source or may define an additional source|
|2 National Funding|
|Note: INTERVALUE partners are expected to pre-define a list of existing national funding sources for product development available for the country and advisors will check whether the proposed product is relevant for that funding source or may define an additional source|
|1. … LR 4/2005 (Friuli Venezia Giulia regional law for the development of innovative projects whose objective is the company growth)
2. …LR 26/2005 (Friuli Venezia Giulia regional law on innovation)
|3 Private funding|
|Note: INTERVALUE partners are expected to pre-define a list of existing private funding sources for product development available for the country and advisors will check whether the proposed product is relevant for that funding source or may define an additional source|
|1. …Business Angel/Venture capitalist
SECTION 3: FINAL EVALUATION
|It is requested a final evaluation considering the funding opportunities you believe most suitable for the exploitation of the R&D result, considering the possibility of the creation of a spin-off, further research, in particular, a cost/benefit analysis and a financial projection for the R&D result, type of collaboration identified (i.e. Licensing Agreement, Technical Cooperation, Joint Venture, Manufacturing Agreement, Commercial Agreement with Technical Assistance, Creation of a spin-off, Joint further development)…|
|CRO is one of the most important National Cancer Institutes.
CRO should invest in the miCRO software project in order think about the opportunity of a partnership with a company that produces cancer treatment infrastructures.
It should be strategic indeed to sell the software via web and to propone a demo within the CRO website.
Decision of evaluation (Please tick as appropriate)
|þ||The R&D has a high potential of exploitation|
|The R&D result needs minor revisions|
|The R&D result needs moderate revisions|
|The R&D result needs major revisions|
|The R&D result has no potential of exploitation|